REGISTRATION IS REQUIRED FOR THIS WEBINAR
This webinar, jointly hosted with the NGO Delegation and Communities Delegation to the Unitaid Board, will explore the opportunities and challenges in making long-acting medicines for ART available to all who need them.
As the landscape of HIV treatment and prevention evolves, long-acting formulations are emerging as a transformative tool in improving treatment adherence — expanding choice and ensuring equitable access, particularly for communities most in need. The long-acting injectable, lenacapavir LA, has shown immense promise for HIV prevention, with results from clinical trials showing that 99.9% of study participants who received lenacapavir LA did not acquire HIV. Long-acting antiretroviral therapy (ART) could offer a critical opportunity to lessen the burden on people receiving ART and reduce the strain on health system resources, transforming HIV treatment and prevention globally. Despite this potential, the scale-up of these newer formulations faces the acute funding crisis caused by shifts in U.S. global health policy.
Date: Thursday, April 17, 2025
Time: 3:00 p.m. - 4:30 p.m. SAST and CET / 9:00 a.m. - 10:30 a.m. ET
